Xi says China ready to boost global COVID-19 vaccine cooperation | WeForNews | Latest News, Blogs Xi says China ready to boost global COVID-19 vaccine cooperation – WeForNews | Latest News, Blogs
Connect with us

Health

Xi says China ready to boost global COVID-19 vaccine cooperation

He also called for stronger international policy coordination to establish travel “fast tracks” that would facilitate orderly global movement.

Published

on

Xi Jinping

BEIJING: President Xi Jinping said on Saturday that China is ready to step up global COVID-19 vaccine cooperation, and called for better international coordination on policies to facilitate movement of people.

Pharmaceutical companies and research centres around the world are working on potential COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants underway. China has five home-grown candidates undergoing Phase III trials.

“China is willing to strengthen cooperation with other countries in the research and development, production, and distribution of vaccines,” Xi told the G20 Riyadh Summit via video link.

“We will fulfill our commitments, offer help and support to other developing countries, and work hard to make vaccines a public good that citizens of all countries can use and can afford,” he said.

He also called for stronger international policy coordination to establish travel “fast tracks” that would facilitate orderly global movement.

With that in mind, Xi said China would propose the creation of a mechanism by which travellers’ coronavirus test results were recognised internationally through digital health codes.

Health

May vaccinate those infected with Covid or having its antibodies: Govt

Published

on

By

Vaccine Covid

New Delhi, Dec 1: The Union Health Ministry hinted on Tuesday that the people infected with Covid-19 or those who have recovered and exhibit antibodies against the viral disease could also come under the ambit of vaccination drive for the immunisation of people against the coronavirus infection.

Union Health Secretary Rajesh Bhushan said that this process is already in the mandate of a national expert group for vaccine administration, headed by V.K. Paul, member, NITI Aayog (health). “They are contemplating the issue, but nothing is concrete as yet,” he said while addressing a press conference.

Bhushan also said that many countries are contemplating the matter of whether patients suffering from Covid-19 or those who have developed its antibodies should be included in the immunisation drive.

Meanwhile, divulging into the technicalities of the matter, Balram Bhargava, Director-General (DG), Indian Council of Medical Research (ICMR), said, “There are two important issues linked with the immunisation of such a set of people. If someone has antibodies against the Covid-19 infection, and a vaccine is given to that person, would he or she develop any vaccine associated adverse reaction? Secondly, if we consider the presence of antibodies and avoid the administration of vaccines to the person, would we be able to spare our vaccine doses?”

However, answering the points raised, Bhargava said that there are enough data from different trials that show that the vaccine related adverse reaction does not happen even if the dose is administered to a person having active Covid infection. “However, the discussion is still going on internationally regarding its implementation,” he added.

Bhargava also said that the World health Organization (WHO) has clearly stated after assessment of the solidarity trials of the vaccines that one does not need to measure the antibodies before administering the vaccine or even find out if the person receiving the dose has contracted the Covid-19 disease. “The current mandate of WHO gives a go-ahead for vaccination to such a set of people,” he added.

The Centre has formed tentative guidelines for vaccine administration to the priority groups. The government has divided the prioritisation under four groups — healthcare workers, people above 65 years of age, people aged between 50 and 65 years, and lastly, people below 50 years with underlying conditions.

Continue Reading

Health

Moderna Says Vaccine 100% Effective Against Severe Covid, Seeks Clearance

COVID-19 Vaccine: Moderna said it expects to have approximately 20 million doses of the vaccine, called mRNA-1273, available in the US by the end of the year.

Published

on

Covid 19 Vaccine

Washington: Moderna Inc will apply for US and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said. Moderna also reported that the vaccine’s efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100% success rate in preventing severe cases of a disease that has killed nearly 1.5 million people.

The filing sets Moderna’s product up to be the second vaccine likely to receive US emergency use authorization this year following a shot developed by Pfizer and BioNTech which had a 95% efficacy rate in trials. “We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it,” Moderna Chief Medical Officer Tal Zaks said.

“We expect to be playing a major part in turning around this pandemic.”

Of the 196 volunteers who contracted COVID-19 in the trial with more than 30,000 people, 185 received a placebo while 11 got the vaccine.

Moderna reported 30 severe cases — all in the placebo group — which means the vaccine was 100% effective in preventing severe cases.

“As the numbers of cases reported grows, confidence grows that this amazing protection will be maintained in a product that can be rolled out to protect the public,” said Alexander Edwards, associate professor in biomedical technology at Britain’s University of Reading.

In addition to filing its US application, Moderna said it would seek conditional approval from the European Medicines Agency, which has already begun a rolling review of its data, and would continue to talk with other regulators.

Pfizer has already applied for emergency use authorization in the United States and Europe, putting it about a week ahead of Moderna.

Moderna said it was on track to have about 20 million doses of its vaccine ready to ship in the United States by the end of 2020, enough to inoculate 10 million people.

Both of the vaccines use a new technology called synthetic messenger RNA (mRNA) whereas others, such as Britain’s AstraZeneca, are using more traditional methods to develop their vaccines.

AstraZeneca has announced an average efficacy rate of 70% for its shot and as much as 90% for a subgroup of trial participants who got a half dose, followed by a full dose.

But some scientists have expressed doubts about the robustness of the 90% efficacy figure for the smaller group.

Moderna’s latest efficacy result is slightly lower than an interim analysis released on Nov 16 of 94.5% effectiveness, a difference that Mr Zaks said was not statistically significant.

“At this level of effectiveness, when you just do the math of what it means for the pandemic that’s raging around us, it’s just overwhelming,” said Zaks, who said he cried when he saw the final results over the weekend.

Both the Moderna and Pfizer vaccines proved more effective than anticipated and were far superior to the 50% benchmark set by the US Food and Drug Administration (FDA).

The past few weeks of positive vaccine results have ignited hopes for an end to a pandemic that has battered economies and comes as new infections and COVID-19 hospitalizations are at record levels across the United States.

Independent advisers to the FDA are scheduled to meet on December 17 to review Moderna’s trial data and make a recommendation to the FDA.

They will meet on December 10 to review Pfizer’s data. Shortly after gaining emergency use authorization, Moderna expects the vaccine to be shipped to distribution points throughout the United States by the government’s Operation Warp Speed program and McKesson Corp, a drug distributor contracted by the US government.

Its distribution is expected to be easier than Pfizer’s because while it needs to be stored in a freezer, it does not require the ultra-cold temperature needed by Pfizer’s vaccine.

Moderna said the 196 COVID-19 cases in its trial included 33 adults over 65 years old and 42 volunteers from racially diverse groups, including 29 Latinos, 6 Blacks, 4 Asian Americans and 3 multiracial participants. There was one death related to COVID-19 in the placebo group.

Azra Ghani, chair in infectious disease epidemiology at Imperial College London, said Monday’s details from Moderna confirmed the vaccine was highly efficient, including against severe cases. “Whilst this does not exclude some risk of severe disease after vaccination given the relatively small number of severe cases, these results suggest very high efficacy,” she said.

Zaks said the vaccine has been developed during a period of “political acrimony” and having a highly effective vaccine may go a long way toward erasing some of that distrust. “This is as black and white as an effect on a population will be. Your chances of actually being sick if you’ve been vaccinated are decreased 20-fold,” he said.

Moderna reported no new side effects since its interim analysis. Based on that analysis, the most common side effects were fatigue, injection site redness and pain, headache and body aches, which rose after the second dose and were short-lived.

Zaks said the vaccine caused significant flu-like symptoms in some participants, which, he said, “goes hand-in-hand with having such a potent vaccine.” But it has not caused any significant safety concerns so far.

Moderna plans to start a new trial to test the vaccine in adolescents before the end of the year, followed by another in even younger volunteers early in 2021.

It hopes to have the vaccine available for adolescents by September, Zaks said.

Other vaccine makers have said they are studying their vaccines in young people as well.

Continue Reading

Health

Modi interacts with 3 teams developing corona vaccines

The Prime Minister also asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters.

Published

on

By

Narendra Modi

New Delhi, Nov 30: Prime Minister Narendra Modi on Monday held virtual meetings with three teams working on the development and manufacture of vaccines against Covid-19, and discussed the potential of various platforms for vaccine development.

The teams are from Gennova Biopharmaceuticals Ltd at Pune, and Biological E Ltd and Dr Reddy’s Laboratories Ltd at Hyderabad.

Their potential vaccines are in different stages of trials and detailed data and results are expected from early next year onwards, a Prime Minister’s Office (PMO) statement said on Monday.

“The potential of various platforms for vaccine development was also discussed,” the statement said.

The Prime Minister also asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters.

He also suggested that they should make extra efforts to inform the general public in simple language about the vaccine and related matters such as its efficacy.

Matters relating to logistics, transport and cold chains in respect of delivery of the vaccines were also discussed.

The Prime Minister advised all departments concerned to engage with the manufacturers and seek to resolve matters so that the efforts by these companies bear fruit in order to serve the needs of the country and the entire world.

The Prime Minister praised the efforts made by scientists and researchers in these companies to come out with a vaccine solution to tackle the ongoing coronavirus pandemic, which so far has infected 94,31,692 people across the country, and led to deaths of 1,37,139 patients.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.